Phase 2 N=15 FOLFOXIRI Plus Panitumumab Patients With Metastatic KRAS Wild-Type Colorectal Cancer With Liver Metastases Only
Colorectal Cancer
Primary: Overall Response Rate (ORR) — 75 percentage of evaluable participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=80 A Study of Avastin (Bevacizumab) in Combination With mFOLFOX-6 or FOLFOXIRI in Patients With Metastatic Colorectal Cancer.
Colorectal Cancer
Primary: Percentage of Participants With Complete Resection or Residual (Microscopic or Macroscopic) Tumor — 48.7; 61.0; 33.3; 51.2 percentage of participants — p=0.2707
N/A N=530 FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer
Colorectal Cancer · Colorectal Carcinoma · Liver Metastases
Primary: Progression-Free Survival (PFS) at Any Site — 10.7; 10.2 Months — p=0.551
Phase 4 N=50 A Study of Bevacizumab Plus 5-Flurouracil (5-FU) Based Doublet Chemotherapy as Neoadjuvant Therapy for Participants With Previously Untreated Unresectable Liver-Only Metastases From Colorectal Cancer
Colorectal Cancer
Primary: Percentage of Participants Achieving Complete Resection (R0 Resection) — 30.0 percentage of participants
Phase 3 N=209 FOLFOX6m Plus SIR-Spheres Microspheres vs FOLFOX6m Alone in Patients With Liver Mets From Primary Colorectal Cancer
Colorectal Cancer Metastatic
Primary: Overall Survival (OS) — 25.9; 25.0 months — p=0.43
Phase 2 N=20 A Study With Neoadjuvant mFOLFOX7 Plus Cetuximab to Determine the Surgical Conversion Rate for Unresectable Colorectal Cancer With Metastases Confined to the Liver
Metastatic Colorectal Cancer
Primary: The Percentage of Patients Who Had a Curative (R0) Liver Metastasectomy Following Protocol Treatment, i.e., Metastatic Disease That Can be Completely Resected and/or…
Phase 2 N=49 Liver Resection and Floxuridine Plus Fluorouracil and Leucovorin in Treating Patients With Liver Metastases From Colorectal Cancer
Colorectal Cancer · Metastatic Cancer
Primary: 2 Year Disease-free Survival . — 9 percentage of participants
Phase 2 N=77 A Study of Bevacizumab and Modified FOLFOX-6 (mFOLFOX-6) in Participants With Metastatic Colorectal Cancer
Colorectal Cancer
Primary: Objective Response Rate (ORR) in the Intent-to-treat (ITT) Analysis Set — 54.5 percentage of participants
N/A N=210 An Observational Study on Bevacizumab (Avastin) as First-Line Treatment in Colorectal Cancer Participants With Potentially Resectable Liver Metastases
Colorectal Cancer
Primary: Percentage of Participants Without Detectable Metastatic Disease After Secondary Resection Post Surgery — 84.6 Percentage of participants
Phase 2 N=14 Irinotecan -Eluting LC Bead-M1 (DEBIRI-M1) for Patients With Liver Metastases From Colorectal Cancer
Colorectal Cancer
Primary: Success of DEBIRI-M1 Procedure as a Measure of Feasibility (Percentage of Successful Treatments) — 100 percentage of successful treatments
Phase 2 N=28 Oxaliplatin, Capecitabine, and Cetuximab in Treating Patients With Advanced Liver Cancer
Liver Cancer
Primary: Disease Response Rate — 12.5 percentage of participants with response
Phase 2 N=16 Treatment of Liver Metastases With Electrochemotherapy
Liver Metastases
Primary: Evaluation of Toxicity Related to Electrochemotherapy (Toxicity, Symptoms) — 0; 0; 0 events
Phase 2 N=45 A Study of Avastin (Bevacizumab) in Combination With XELOX in Patients With Metastatic Colorectal Cancer
Colorectal Cancer
Primary: Percentage of Participants With Conversion From Unresectable to Resectable Liver Metastases — 42.2 percentage of participants
Phase 1 N=41 EMD 525797 in Colorectal and Ovarian Cancer Patients With Liver Metastases
Colorectal and Ovarian Cancer Patients With Liver Metastases
Primary: Number of Subjects With Dose Limiting Toxicities (DLTs) — 1; 1; 0; 2 Subjects
Phase 2 N=38 Intra-hepatic Chemotherapy in Patients With Liver Metastases From Breast Cancer and Limited Extrahepatic Disease
Metastatic Breast Cancer · Liver Metastases
Primary: Response Rate — 2; 13; 21; 1 Participants
Phase 2 N=58 Intra-arterial Hepatic Beads Loaded With Irinotecan With Concomitant Chemotherapy With FOLFOX in Patients With Colorectal Cancer With Unresectable Liver Metastases: a Phase II Multicenter Study
Colorectal Cancer With Non Resectable Hepatic Metastasis
Primary: Progression-free Survival Rate at 9 Months — 30; 26 Participants
Phase 2 N=16 Hepatic Arterial Infusion of Floxuridine, Gemcitabine Hydrochloride, and Radiolabeled Monoclonal Antibody Therapy in Treating Liver Metastases in Patients With Metastatic Colorectal Cancer Previously Treated With Surgery
Liver Metastases · Recurrent Colon Cancer · Recurrent Rectal Cancer
Primary: Number of Participants With at Least One Dose Limiting Toxicity — 0; 0; 1 participants with DLTs
Phase 2 N=211 Bevacizumab and Oxaliplatin Combined With Irinotecan or Leucovorin and Fluorouracil in Treating Patients With Metastatic or Recurrent Colorectal Cancer
Colorectal Cancer
Primary: Objective Response Rate — 0.33; 0.38; 0.49 proportion
Phase 2 N=51 BAY 43-9006 Plus Cetuximab to Treat Colorectal Cancer
Metastatic Colorectal Cancer
Primary: Overall Rate of Response — 15 percentage of participants
Phase 2 N=50 Capecitabine, Oxaliplatin, and Bevacizumab in Treating Patients With Metastatic or Recurrent Colorectal Cancer
Colorectal Cancer
Primary: Response Rate (Percentage of Participants With Partial or Complete Response) — 63; 42 percentage of participants with response
Phase 2 N=221 Study Evaluating Biomarkers in Patients With Colorectal Cancer and Native KRAS Treated With Chemotherapy + Cetuximab
Colorectal Cancer
Primary: Progression Free Survival — 11.4; 5.9 Months — p=0.004
Phase 2 N=56 Aflibercept and FOLFOX6 Treatment for Previously Untreated Stage IV Colorectal Cancer
Mucinous Adenocarcinoma of the Colon · Mucinous Adenocarcinoma of the Rectum · Signet Ring Adenocarcinoma of the Colon
Primary: Proportion of Patients Alive and Progression-free at 15 Months — .482 proportion of participants
Phase 2 N=83 Sorafenib and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer
Recurrent Colon Cancer · Recurrent Rectal Cancer · Stage IV Colon Cancer
Primary: Progression-free Survival Rate — 53.2 percentage of participants
Phase 2 N=30 Capecitabine, Cetuximab, Oxaliplatin, and Bevacizumab in Treating Patients With Metastatic or Recurrent Colorectal Cancer That Cannot Be Removed By Surgery
Colorectal Cancer
Primary: Response Rate (Percentage of Participants With Partial or Complete Response) — 43 percentage of participants with response
Phase 2 N=38 Preoperative CRT With or Without Induction Chemotherapy for Rectal Cancer With Liver Metastases
Rectal Cancer · Liver Metastases
Primary: Quality of Surgery for Primary Tumor — 2; 1; 15; 19 Participants — p=0.719
Phase 2 N=70 Drug-Eluting Bead, Irinotecan (DEBIRI) Therapy of Liver Metastasis From Colon Cancer With Systemic Fluorouracil, Oxaliplatin, Leucovorin and Bevacizumab
Colon Cancer With Metastases to the Liver
Primary: Tumor Response — 31; 16 participants
Phase 2 N=34 A Phase I/II Study of Pexa-Vec Oncolytic Virus in Combination With Immune Checkpoint Inhibition in Refractory Colorectal Cancer
Colorectal Cancer · Colorectal Carcinoma · Colorectal Adenocarcinoma
Primary: Number of Participants With Grade 1-5 Adverse Events — 4; 12; 4; 13 Participants
Phase 3 N=175 Colorectal Cancer Metastatic
Colorectal Cancer Metastatic
Primary: Percentage of Participants With Adverse Events (AEs) — 100.00; 40.6; 21.1; 9.1 Percentage of participants
Phase 2 N=7 New Individualized Therapy Trial for Metastatic Colorectal Cancer
Colorectal Neoplasm · Colorectal Cancer
Primary: Number of Patients With Adverse Events — 5; 0 Participants
Phase 1 N=82 MEK and MET Inhibition in Colorectal Cancer
Solid Tumor · Colorectal Cancer
Primary: Maximal Tolerated Dose (MTD) of PD-0325901 and PF-02341066 /PF-02341066 or Binimetinib With PF-02341066 — 0; 0; 0; 1 Dose Limiting Toxicities (DLTs)